Cohere Health vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $50M equity ($106M total). Processes 5.5M prior authorizations/year for 15M health plan members and 420,000 providers. CMS 2026 deadline a direct growth catalyst.
About
Cohere Health (not affiliated with the AI company Cohere) is a prior authorization intelligence platform operating on the payer side of healthcare — a differentiated position from provider-facing prior auth tools. The company has raised $106 million in total equity financing and processes 5.5 million prior authorizations annually covering 15 million health plan members and 420,000 provider relationships for its health plan customers.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.